William Richard White Akero Therapeutics, Inc. (AKRO) insider trading activity

William Richard White is Chief Financial Officer of Akero Therapeutics, Inc.. Currently has a direct ownership of 62,635 shares of AKRO, which is worth approximately $1.77 Million. The most recent transaction as insider was on Dec 16, 2024, when has been sold 24,300 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 62.6K

52.2% 3M change

24.39% 12M change

Total Value Held $1.77 Million

William Richard White Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 16 2024	BUY Grant, award, or other acquisition	-	24,300 Added 27.95%	62,635 Common Stock
Dec 10 2024	SELL Open market or private sale	$86,735 $30.79 p/Share	2,817 Reduced 6.85%	38,335 Common Stock
Sep 10 2024	SELL Open market or private sale	$16,729 $26.18 p/Share	639 Reduced 1.53%	41,152 Common Stock
Aug 27 2024	SELL Open market or private sale	$612,051 $26.41 p/Share	23,175 Reduced 35.67%	41,791 Common Stock
Aug 27 2024	BUY Exercise of conversion of derivative security	$488,760 $21.09 p/Share	23,175 Added 26.29%	64,966 Common Stock
Aug 26 2024	SELL Open market or private sale	$2,045,076 $27.21 p/Share	75,159 Reduced 64.27%	41,791 Common Stock
Aug 26 2024	BUY Exercise of conversion of derivative security	$1,201,792 $15.99 p/Share	75,159 Added 55.65%	59,907 Common Stock
Jul 25 2024	SELL Open market or private sale	$608,693 $27.33 p/Share	22,272 Reduced 34.77%	41,791 Common Stock
Jul 25 2024	BUY Exercise of conversion of derivative security	$156,126 $7.01 p/Share	22,272 Added 25.8%	64,063 Common Stock
Jul 24 2024	SELL Open market or private sale	$3,748,286 $26.95 p/Share	139,083 Reduced 76.89%	41,791 Common Stock
Jul 24 2024	BUY Exercise of conversion of derivative security	$974,971 $7.01 p/Share	139,083 Added 43.47%	180,874 Common Stock
Jul 23 2024	SELL Open market or private sale	$14,005 $28.01 p/Share	500 Reduced 1.18%	41,791 Common Stock
Jul 23 2024	BUY Exercise of conversion of derivative security	$3,505 $7.01 p/Share	500 Added 1.17%	42,291 Common Stock
Jul 16 2024	SELL Open market or private sale	$976,448 $28.05 p/Share	34,811 Reduced 45.44%	41,791 Common Stock
Jul 16 2024	BUY Exercise of conversion of derivative security	$208,919 $7.01 p/Share	29,803 Added 28.01%	76,602 Common Stock
Jun 11 2024	SELL Open market or private sale	$64,093 $22.64 p/Share	2,831 Reduced 5.7%	46,799 Common Stock
Mar 13 2024	SELL Open market or private sale	$20,510 $28.33 p/Share	724 Reduced 1.44%	49,630 Common Stock
Dec 14 2023	SELL Open market or private sale	$12,684 $20.76 p/Share	611 Reduced 1.2%	50,354 Common Stock
Dec 08 2023	BUY Grant, award, or other acquisition	-	32,497 Added 38.94%	50,965 Common Stock
Sep 13 2023	SELL Open market or private sale	$31,814 $50.34 p/Share	632 Reduced 3.31%	18,468 Common Stock
Jun 20 2023	SELL Open market or private sale	$1,142,735 $55.0 p/Share	20,777 Reduced 52.1%	19,100 Common Stock
Jun 20 2023	BUY Exercise of conversion of derivative security	$122,675 $7.01 p/Share	17,500 Added 30.5%	39,877 Common Stock
Jun 13 2023	SELL Open market or private sale	$33,426 $55.16 p/Share	606 Reduced 2.64%	22,377 Common Stock
Mar 10 2023	SELL Payment of exercise price or tax liability	$27,864 $43.47 p/Share	641 Reduced 2.71%	22,983 Common Stock
Dec 28 2022	SELL Open market or private sale	$49,710 $49.76 p/Share	999 Reduced 4.06%	23,624 Common Stock

Also insider at

VTYX

Ventyx Biosciences, Inc. Healthcare

GMTX

Gemini Therapeutics, Inc. Healthcare

WRW